Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates

Drug Metabolism Reviews
Aiming YuFrank J Gonzalez

Abstract

Cytochrome P450 2D6 (CYP2D6) is the first well-characterized polymorphic phase I drug-metabolizing enzyme, and more than 80 allelic variants have been identified for the CYP2D6 gene, located on human chromosome 22q13.1. Human debrisoquine and sparteine metabolism is subdivided into two principal phenotypes--extensive metabolizer and poor metabolizer--that arise from variant CYP2D6 genotypes. It has been estimated that CYP2D6 is involved in the metabolism and disposition of more than 20% of prescribed drugs, and most of them act in the central nervous system or on the heart. These drug substrates are characterized as organic bases containing one nitrogen atom with a distance about 5, 7, or 10 A from the oxidation site. Aspartic acid 301 and glutamic acid 216 were determined as the key acidic residues for substrate-enzyme binding through electrostatic interactions. CYP2D6 transgenic mice, generated using a lambda phage clone containing the complete wild-type CYP2D6 gene, exhibits enhanced metabolism and disposition of debrisoquine. This transgenic mouse line and its wild-type control are models for human extensive metabolizers and poor metabolizers, respectively, and would have broad application in the study of CYP2D6 polymorphis...Continue Reading

References

Sep 17, 1977·Lancet·A MahgoubR L Smith
Jan 1, 1979·Biomedical Mass Spectrometry·O Beck, T R Bosin
Apr 1, 1979·Journal of Neurochemistry·M A RogawskiG K Aghajanian
Mar 1, 1979·British Journal of Clinical Pharmacology·J R IdleR L Smith
Sep 1, 1979·European Journal of Clinical Pharmacology·M EichelbaumH J Dengler
Mar 1, 1992·Chemical Research in Toxicology·L KoymansG M Donné-Op den Kelder
Mar 1, 1992·Clinical Pharmacology and Therapeutics·S H SindrupT C Tasker
Jun 1, 1991·Clinical Pharmacokinetics·A E Balant-GorgiaL P Balant
Jan 1, 1990·European Journal of Clinical Pharmacology·G AlvánU Gundert-Remy
Sep 1, 1990·Journal of Analytical Toxicology·R L KincaidF Rieders
Jun 17, 1989·Lancet·A LlerenaJ Benítez
Dec 1, 1989·British Journal of Clinical Pharmacology·Q Y YueJ Säwe
Mar 1, 1985·British Journal of Clinical Pharmacology·R V LewisH F Woods
Oct 1, 1986·Biochemical Pharmacology·J P SullivanK F Tipton
Nov 19, 1988·BMJ : British Medical Journal·J BeckmannM Eichelbaum
Jun 1, 1988·Naunyn-Schmiedeberg's Archives of Pharmacology·P SchoeffterD Hoyer
Apr 1, 1988·Clinical Pharmacology and Therapeutics·K Brøsen, L F Gram

❮ Previous
Next ❯

Citations

Sep 10, 2005·Journal of Psychoactive Drugs·J C Callaway
Jun 20, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yueying ZhenJeffrey R Idle
Oct 8, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Wei-Yan ZhangAi-Ming Yu
Dec 20, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xi-Ling JiangAi-Ming Yu
Aug 14, 2008·The Journal of Pharmacology and Experimental Therapeutics·Natasha T SniderPaul F Hollenberg
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·Frank J Gonzalez, Ai-Ming Yu
Jun 21, 2013·Malaria Journal·Brandon S PybusVictor Melendez
Jun 23, 2012·The Journal of Clinical Endocrinology and Metabolism·Hadine JoffeJanet E Hall
Dec 4, 2012·Journal of Psychiatry & Neuroscience : JPN·Sharon Miksys, Rachel F Tyndale
Jul 4, 2008·Pharmacogenomics·Idilio GonzálezAdrián LLerena
Apr 21, 2009·Pharmacogenomics·Monique J BijlBruno H Ch Stricker
Jun 29, 2007·Bioinformation·Tresa Remya Thomas Antony, Shanthi Nagarajan
Nov 7, 2013·Pharmacogenomics·Anders Helldén, Parvaz Madadi
Jul 13, 2011·Proceedings of the National Academy of Sciences of the United States of America·Alice A ChenSangeeta N Bhatia
Dec 4, 2010·Evidence-based Complementary and Alternative Medicine : ECAM·Gaofeng LiuZhiren Zhang
Feb 9, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xi-Ling JiangAi-Ming Yu
Nov 26, 2009·Expert Opinion on Drug Metabolism & Toxicology·M FilopantiA Spada
Sep 1, 2009·Expert Opinion on Drug Metabolism & Toxicology·Katsutoshi Yoshizato, Chise Tateno
Sep 22, 2010·Drug Metabolism Reviews·Xi-Ling JiangAi-Ming Yu
Jan 3, 2013·European Journal of Internal Medicine·Silvio CacciaAlessandro Nobili
Sep 14, 2010·Molecular Genetics and Metabolism·T WassenbergM M Verbeek
Oct 9, 2008·Biochemical and Biophysical Research Communications·Hiroshi SuemizuMasato Nakamura
Jun 6, 2008·Journal of Clinical Pharmacology·J Andrew WilliamsSteven A Wrighton
Dec 24, 2010·Journal of Gastroenterology and Hepatology·Kazuaki ChayamaMichio Imamura
Mar 1, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Akihide Kamiya, Atsushi Miyajima
Sep 17, 2013·British Journal of Clinical Pharmacology·Eva M Peñas-Lledó, Adrián Llerena
Mar 12, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Muhammad FarooqJashvant D Unadkat
Apr 26, 2013·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Jie ChengFrank J Gonzalez
Mar 31, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Angus N R NeddermanDavid Higton
Jun 17, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Yanwen ChengMei Dong

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.